Tag Archive for: 177Lu-PSMA-617

EVOLUTION Trial Ipilimumab And Nivolumab Plus 177Lu‑PSMA‑617 in mCRPC

Phase II EVOLUTION is a randomized study testing whether adding ipilimumab and nivolumab to 177Lu‑PSMA‑617 improves outcomes versus 177Lu‑PSMA‑617 alone in men with metastatic castration‑resistant prostate cancer (mCRPC). Early data presented in 2025 indicate that at 12 months, 33% of patients on the combination were free of progression versus 17% on 177Lu‑PSMA‑617 alone, signaling a […]

New Trial for AMO959 and Pluvicto and ARSI Combo

The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]

177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial

City of Hope Medical Center, in collaboration with the National Cancer Institute, is initiating a randomized phase 1 study in metastatic castration‑resistant prostate cancer (mCRPC) that compares lutetium Lu 177 vipivotide tetraxetan (177Lu‑PSMA‑617 or Pluvicto) alone versus the same radioligand combined with sipuleucel‑T, with the primary goal of quantifying the induced anti‑tumor immune response alongside […]

Pluvicto extends disease control in advanced hormone-sensitive prostate cancer

The Phase III PSMAddition trial presented at the 2025 European Society for Medical Oncology Congress marks a meaningful advance in the treatment of prostate cancer that still responds to hormonal therapy but has already spread to distant sites. In this study, patients with prostate-specific membrane antigen–positive metastatic hormone-sensitive prostate cancer received the radioligand therapy Pluvicto […]